Anterogen.Co.Ltd vs Torrent Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how Anterogen.Co.Ltd (065660) and Torrent Pharmaceuticals (500420) compare, as of Aug 15, 2026.
As of Aug 15, 2026, Fair Value Calculator sees Torrent Pharmaceuticals as the less overvalued of the two: Anterogen.Co.Ltd trades at KRW 15,980 versus a fair value of KRW 4,741 (-70%), while Torrent Pharmaceuticals trades at ₹4,840 versus ₹4,360 (-10%).
Anterogen.Co.Ltd
065660.KQ · KRW · Health Care
-70%
upside to fair value
overvalued
PriceKRW 15,980
Fair ValueKRW 4,741
Quality43/100
Torrent Pharmaceuticals
500420.BSE · INR · Health Care
-10%
upside to fair value
fairly valued
Price₹4,840
Fair Value₹4,360
Quality53/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Anterogen.Co.LtdTorrent Pharmaceuticals
Valuation
—P/E (TTM)37.8×
0.02×P/S (TTM)—
—P/B0.05×
—EV/EBITDA3.8×
Profitability
-86%Net margin0%
-54%Operating margin0%
-232%Return on equity—
-2%Return on assets0%
Growth
-14%Revenue growth (YoY)0%
4.6%Avg. growth/yr (3Y)12.7%
12.7%Avg. growth/yr (5Y)11.4%
Balance & size
0.12×Debt / equity1.39×
$128MMarket cap$4B
expensiveGrowth qualityhealthy
Torrent Pharmaceuticals leads: 2 to 5 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Anterogen.Co.Ltdof which business quality 43 · market factors 18Torrent Pharmaceuticalsof which business quality 52 · market factors 75
ProfitabilityMargins and returns on capital today
6
51
Quality GrowthAre margins and returns improving?
47
40
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
97
44
Low VolatilityCalm price path (market factor)
50
86
MomentumPrice trend over the last 3–12 months (market factor)
6
68
52W MomentumDistance to the 52-week high (market factor)
3
75
Net IssuanceBuybacks instead of dilution
63
82
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Anterogen.Co.Ltd
Asset-BasedKRW 5,855
1 of 1 models see the stock below the current price.
Torrent Pharmaceuticals
DCF Models₹5,769
Earnings-Based₹2,922
Multiples₹5,306
Asset-Based₹707
Growth DCF₹5,288
Economic Profit₹3,266
Growth Earnings₹5,013
9 of 24 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Anterogen.Co.Ltd
Bear KRW 3,129Fair Value KRW 4,741Bull KRW 5,926
KRW 15,980 = current price (white tick)
Torrent Pharmaceuticals
Bear ₹1,984Fair Value ₹4,360Bull ₹7,472
₹4,840 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Anterogen.Co.Ltd · Health Care
Quality score43 · below median
Fair value upside-70% · bottom 25%
Torrent Pharmaceuticals · Health Care
Quality score53 · above median
Fair value upside-10% · above median
Bottom line
As of Aug 15, 2026, Fair Value Calculator sees Torrent Pharmaceuticals as the less overvalued of the two: Anterogen.Co.Ltd trades at KRW 15,980 versus a fair value of KRW 4,741 (-70%), while Torrent Pharmaceuticals trades at ₹4,840 versus ₹4,360 (-10%).
Torrent Pharmaceuticals has the higher quality score (53/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
